39 results
8-K/A
EX-99.3
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that a drug candidate does not undergo … , buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling
8-K/A
EX-99.2
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
for the manufacture of drug substance, the manufacture of drug product, and the packaging of drug product for clinical use. This reliance on contract … for the manufacture, processing, packaging, or holding of human drugs must comply with applicable cGMP regulations.
Delays in designing and completing
424B3
2c57s3h
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
89v083vwu
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
9nusof
10 May 23
Registration of securities issued in business combination transactions
9:56pm
425
EX-2.1
jcfvudjaqxod
30 Mar 23
Business combination disclosure
8:51am
8-K
EX-2.1
t4h27gyw0f433ia hmrn
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
8-K
EX-1.1
d8w3j ah8yrkemn4
18 Feb 21
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
4:52pm
8-K
EX-10.1
leqjl 5i4t2d3w6a
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-10.1
6eie09
13 Dec 19
Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
4:19pm
8-K
EX-10.2
6uuqsf2v1cshs5mz
13 Nov 19
Diffusion Pharmaceuticals Announces $4.0 Million Public Offering
5:00pm